Equity MRK
Friday, May 14, 2021   
Asian Paints  2773.60    (8.51%)
 
Axis Bank  685.10    (-0.90%)
 
Bajaj Auto  3848.35    (-0.78%)
 
Bajaj Finance  5327.95    (-0.55%)
 
Bajaj Finserv  10968.10    (-1.07%)
 
Bharti Airtel  560.55    (-0.22%)
 
Dr Reddy's Lab...  5195.85    (-2.00%)
 
H D F C  2421.80    (-0.69%)
 
HCL Technologi...  910.30    (0.45%)
 
HDFC Bank  1387.15    (-0.88%)
 
Hind. Unilever  2376.80    (2.05%)
 
ICICI Bank  597.25    (0.39%)
 
IndusInd Bank  891.40    (-2.82%)
 
Infosys  1316.80    (-0.76%)
 
ITC  212.35    (4.45%)
 
Kotak Mah. Ban...  1707.30    (-0.65%)
 
Larsen & Toubr...  1415.50    (2.21%)
 
M & M  741.65    (-2.45%)
 
Maruti Suzuki  6738.15    (-1.21%)
 
Nestle India  17217.55    (3.01%)
 
NTPC  111.30    (-1.72%)
 
O N G C  113.00    (-1.78%)
 
Power Grid Cor...  228.80    (1.33%)
 
Reliance Indus...  1936.85    (1.22%)
 
St Bk of India  360.50    (-2.00%)
 
Sun Pharma.Ind...  691.10    (-1.64%)
 
TCS  3050.75    (-1.22%)
 
Tech Mahindra  951.95    (-1.05%)
 
Titan Company  1456.00    (0.08%)
 
UltraTech Cem.  6367.70    (-0.38%)
 
Market Menu
plusminDaily Market Tracker
plusminNews
Corporate Information
Corporate Actions
Other Markets
Close
You are here : Equity | News | Hot Pursuit
Bajaj Healthcare soars on launching Favipiravir tablets for COVID-19 treatment
(15:15, 04 May 2021)

In a regulatory filing made during market hours today, the company said that the tablets comprising Favipiravir in different dosage forms is used for the treatment of mild to moderate COVID-19 disease. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus.

The company has successfully developed the active pharmaceutical ingredient (API) and the formulation for Favipiravir through its own in-house R&D team. Most patients ailing from mild to moderate symptoms can benefit from the use of Favijaj. The drug will be available as a prescription-based medication, with recommended doses.

The drug controller of India's has granted permissions to supply the Favijaj (Favipiravir) in the domestic as well as in overseas market.

Anil Jain, Joint Managing director, Bajaj Healthcare, said: We are pleased to add Favipiravir to our growing product portfolios. The second waves is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure, and offer patients much needed and timely therapy option.

Bajaj Healthcare is a leading manufacturer of APIs, intermediates and formulations.

The company's net profit surged to Rs 326.1% to Rs 26.42 crore on a 79.6% to Rs 178.33 crore in Q3 FY21 over Q3 FY20.

Powered by Capital Market - Live News